{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:26:56Z","timestamp":1793287616458,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.contraception.2021.05.002","type":"journal-article","created":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T06:36:20Z","timestamp":1621060580000},"page":"222-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5967-8180","authenticated-orcid":false,"given":"Mitchell D.","family":"Creinin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn L.","family":"Westhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2258-058X","authenticated-orcid":false,"given":"C\u00e9line","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Kaunitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7478-8262","authenticated-orcid":false,"given":"Sharon L.","family":"Achilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Foidart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.contraception.2021.05.002_bib0001","first-page":"299","article-title":"Pharmacological profile of estrogens in oral contraception","volume":"63","author":"Bitzer","year":"2011","journal-title":"Minerva Ginecol"},{"issue":"6","key":"10.1016\/j.contraception.2021.05.002_bib0002","doi-asserted-by":"crossref","first-page":"R221","DOI":"10.1530\/EJE-14-0527","article-title":"Epidemiology of hormonal contraceptives-related venous thromboembolism","volume":"171","author":"Hugon-Rodin","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.contraception.2021.05.002_bib0003","article-title":"Combined oral contraceptives: venous thrombosis","author":"de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.contraception.2021.05.002_bib0004","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/AOG.0b013e3182a1741c","article-title":"Norethindrone acetate 1.0 milligram and ethinyl estradiol 10 micrograms as an ultra low-dose oral contraceptive","volume":"122","author":"Archer","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2021.05.002_bib0005","article-title":"20 microg versus >20 microg estrogen combined oral contraceptives for contraception","volume":"8","author":"Gallo","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"3 Pt 1","key":"10.1016\/j.contraception.2021.05.002_bib0006","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0002-9378(98)70047-X","article-title":"Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons","volume":"179","author":"Rosenberg","year":"1998","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.contraception.2021.05.002_bib0007","article-title":"20 \u00b5g versus >20 \u00b5g estrogen combined oral contraceptives for contraception","volume":"2013","author":"Gallo","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2021.05.002_bib0008","first-page":"207","article-title":"Metabolism of 17-beta-oestradiol-4-14-C in early infancy","volume":"49","author":"Hagen","year":"1965","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"10","key":"10.1016\/j.contraception.2021.05.002_bib0009","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.15252\/emmm.201404112","article-title":"The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor alpha modulation, uncoupling nuclear and membrane activation","volume":"6","author":"Abot","year":"2014","journal-title":"EMBO Mol Med"},{"issue":"3","key":"10.1016\/j.contraception.2021.05.002_bib0010","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1152\/physrev.00024.2016","article-title":"Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications","volume":"97","author":"Arnal","year":"2017","journal-title":"Physiol Rev"},{"issue":"13","key":"10.1016\/j.contraception.2021.05.002_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.008950","article-title":"Predominant role of nuclear versus membrane estrogen receptor alpha in arterial protection: implications for estrogen receptor alpha modulation in cardiovascular prevention\/safety","volume":"7","author":"Guivarc'h","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.contraception.2021.05.002_bib0012","series-title":"Sex steroids' effects on brain, heart and vessels, Vol. 6: frontiers in gynecological endocrinology","article-title":"Unique vascular benefits of estetrol, a native fetal estrogen with specific actions in tissues (NEST)","author":"Foidart","year":"2019"},{"issue":"1","key":"10.1016\/j.contraception.2021.05.002_bib0013","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1530\/JOE-14-0549","article-title":"Estetrol is a weak estrogen antagonizing estradiol-dependent mammary gland proliferation","volume":"224","author":"Gerard","year":"2015","journal-title":"J Endocrinol"},{"issue":"6","key":"10.1016\/j.contraception.2021.05.002_bib0014","first-page":"463","article-title":"Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives","volume":"20","author":"Mawet","year":"2015","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"2","key":"10.1016\/j.contraception.2021.05.002_bib0015","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.contraception.2016.08.018","article-title":"Reduced haemostatic effects with drospirenone-based oral contraceptives containing estetrol versus ethinyl estradiol","volume":"95","author":"Kluft","year":"2017","journal-title":"Contraception"},{"issue":"6","key":"10.1016\/j.contraception.2021.05.002_bib0016","first-page":"476","article-title":"Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: results of a phase II dose-finding pilot study","volume":"20","author":"Duijkers","year":"2015","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2021.05.002_bib0017","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.contraception.2016.04.015","article-title":"Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA)","volume":"94","author":"Apter","year":"2016","journal-title":"Contraception"},{"issue":"4","key":"10.1016\/j.contraception.2021.05.002_bib0018","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/13625187.2017.1336532","article-title":"Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control","volume":"22","author":"Apter","year":"2017","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"6","key":"10.1016\/j.contraception.2021.05.002_bib0019","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.contraception.2020.08.015","article-title":"Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters","volume":"102","author":"Douxfils","year":"2020","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2021.05.002_bib0020","unstructured":"FDA draft Guidance for Industry (2019): Establishing effectiveness and safety for hormonal drug products intended to prevent pregnancy. https:\/\/www.fda.gov\/media\/128792\/download (accessed March 13, 2021)."},{"key":"10.1016\/j.contraception.2021.05.002_bib0021","unstructured":"The EMEA CHMP guideline on clinical investigation of steroid contraceptives in women. https:\/\/www.ema.europa.eu\/en\/clinical-investigation-steroid-contraceptives-women (accessed on December 22, 2020)."},{"issue":"4","key":"10.1016\/j.contraception.2021.05.002_bib0022","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/GRF.0b013e318159bf8a","article-title":"Study design to evaluate the safety and effectiveness of hormonal contraception for women","volume":"50","author":"Kapp","year":"2007","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.contraception.2021.05.002_bib0023","unstructured":"Declaration of Helsinki (18th WMA General Assembly 1964), revised at 64th World Medical Association General Assembly, Fortaleza, Brazil. 2013."},{"key":"10.1016\/j.contraception.2021.05.002_bib0024","unstructured":"ICH Topic E6(R2). Guideline for good clinical practice (CPMP\/ICH\/135\/95). 2016."},{"key":"10.1016\/j.contraception.2021.05.002_bib0025","series-title":"Medical eligibility criteria for contraceptive use","year":"2010"},{"issue":"1","key":"10.1016\/j.contraception.2021.05.002_bib0026","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.contraception.2006.08.012","article-title":"Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials","volume":"75","author":"Mishell Jr","year":"2007","journal-title":"Contraception"},{"issue":"8","key":"10.1016\/j.contraception.2021.05.002_bib0027","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1016\/S2214-109X(19)30265-7","article-title":"Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials","volume":"7","author":"Archer","year":"2019","journal-title":"Lancet Glob Health"},{"issue":"5","key":"10.1016\/j.contraception.2021.05.002_bib0028","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.contraception.2013.04.001","article-title":"The creeping Pearl: why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills?","volume":"88","author":"Trussell","year":"2013","journal-title":"Contraception"},{"issue":"11","key":"10.1016\/j.contraception.2021.05.002_bib0029","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/aje\/kwm221","article-title":"Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth","volume":"166","author":"Brunner Huber","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.contraception.2021.05.002_bib0030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/AOG.0b013e31820095a2","article-title":"Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen","volume":"117","author":"Dinger","year":"2011","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.contraception.2021.05.002_bib0031","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.contraception.2009.04.011","article-title":"Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity","volume":"80","author":"Edelman","year":"2009","journal-title":"Contraception"},{"issue":"6","key":"10.1016\/j.contraception.2021.05.002_bib0032","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.contraception.2010.01.016","article-title":"Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women","volume":"81","author":"Westhoff","year":"2010","journal-title":"Contraception"},{"issue":"4","key":"10.1016\/j.contraception.2021.05.002_bib0033","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/AOG.0000000000003189","article-title":"Influence of genetic variants on steady-state etonogestrel concentrations among contraceptive implant users","volume":"133","author":"Lazorwitz","year":"2019","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.contraception.2021.05.002_bib0034","doi-asserted-by":"crossref","first-page":"E646","DOI":"10.9778\/cmajo.20190087","article-title":"Household income and contraceptive methods among female youth: a cross-sectional study using the Canadian Community Health Survey (2009-2010 and 2013-2014)","volume":"7","author":"Nethery","year":"2019","journal-title":"CMAJ Open"},{"issue":"7","key":"10.1016\/j.contraception.2021.05.002_bib0035","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1124\/dmd.105.003822","article-title":"CYP3A5 genetic polymorphisms in different ethnic populations","volume":"33","author":"Roy","year":"2005","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.contraception.2021.05.002_bib0036","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.contraception.2020.11.011","article-title":"Efficacy, safety, and tolerability of a levonorgestrel\/ethinyl estradiol transdermal delivery system: phase 3 clinical trial results","volume":"103","author":"Nelson","year":"2021","journal-title":"Contraception"},{"issue":"3","key":"10.1016\/j.contraception.2021.05.002_bib0037","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1055\/s-0037-1613379","article-title":"Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use","volume":"89","author":"Abdollahi","year":"2003","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.contraception.2021.05.002_bib0038","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.contraception.2019.02.001","article-title":"Segesterone acetate\/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation","volume":"99","author":"Gemzell-Danielsson","year":"2019","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2021.05.002_bib0039","unstructured":"U.S. Census Bureau, Quick facts, population estimates, 2019. Available at: https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/PST045219 (accessed March 13, 2021)."}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782421001499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782421001499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T21:11:47Z","timestamp":1762117907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782421001499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0010782421001499"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2021.05.002","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2021.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}